Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation
dc.contributor.author | Ayanoglu, Muge | |
dc.contributor.author | Korgali, Elif | |
dc.contributor.author | Sezer, Taner | |
dc.contributor.author | Aydin, Halil Ibrahim | |
dc.contributor.author | Sonmez, Fatma Mujgan | |
dc.contributor.orcID | 0000-0002-2278-1827 | en_US |
dc.contributor.orcID | 0000-0001-7994-4394 | en_US |
dc.contributor.pubmedID | 32173091 | en_US |
dc.contributor.researcherID | AAJ-5931-2021 | en_US |
dc.date.accessioned | 2021-06-21T06:48:36Z | |
dc.date.available | 2021-06-21T06:48:36Z | |
dc.date.issued | 2020 | |
dc.description.abstract | We describe the first child with guanidinoacetate methyltransferase (GAMT) deficiency who developed neuroleptic malignant syndrome (NMS) after the treatment of risperidone without elevated creatine kinase (CK) levels. The patient presented with lethargy, hyperthermia, generalized tremor and rigidity with normal serum CK levels. After cessation of risperidone and adding clonezepam to the supportive treatment, symptoms of NMS were ameliorated. We conclude that although serum CK elevation is a useful indicator for the early detection of NMS, normal serum CK levels may be seen during the NMS course in the presence of GAMT deficiency. (C) 2020 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved. | en_US |
dc.identifier.endpage | 420 | en_US |
dc.identifier.issn | 0387-7604 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.scopus | 2-s2.0-85081701781 | en_US |
dc.identifier.startpage | 418 | en_US |
dc.identifier.uri | http://hdl.handle.net/11727/6121 | |
dc.identifier.volume | 42 | en_US |
dc.identifier.wos | 000527287200008 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.braindev.2020.02.001 | en_US |
dc.relation.journal | BRAIN & DEVELOPMENT | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Guanidinoacetate methyltransferase (GAMT) deficiency | en_US |
dc.subject | Neuroleptic malignant syndrome | en_US |
dc.subject | Normal creatine kinase levels | en_US |
dc.title | Coexistence of guanidinoacetate methyltransferase (GAMT) deficiency and neuroleptic malignant syndrome without creatine kinase elevation | en_US |
dc.type | article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: